Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0121

Medical education · Dr. Daniel Vogel

27 Apr 2026 · Virtual · Dr. Daniel Vogel, LMU Klinikum München · MSL Dr. Anna Becker · Nephrada

ReviewedManualENG-0121—

Capture insight from this engagement

Location: LMU Klinikum München
Therapeutic area: Nephrology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

eGFR slope interpretation
Proteinuria as surrogate endpoint

Scientific content used

Surrogate-endpoint evidence review

Questions raised

What is the immunoglobulin monitoring recommendation?

Notes

Medical education with academic nephrologist at LMU Klinikum München. Discussed egfr slope interpretation, proteinuria as surrogate endpoint.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0121

Audit history (0)

All create, update and approval events for this record

No audit events in sample data